Vinpocetine, cognition, and epilepsy

Meador, Kimford J.; Leeman-Markowski, Beth A.; Medina, Alexandre E.; Illamola, Sílvia M.; Seliger, Jordan; Novak, Gloria; Lin, Chung‐Wei Christine; Ivanisevic, Mirjana; Razavi, Babak; Marino, Susan E.; Boyd, Alan; Loring, David W.

doi:10.1016/j.yebeh.2021.107988

Cited by 13 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beneficial effects on memory and cognition have been reported 14 . In the study of Meador et al, no significant cognitive improvement was observed using small vinpocetine doses (maximum of 60 mg/day) in patients with and without epilepsy, and there were no significant adverse effects 15 . The doses they used were lower than those described in animal models.…”

Section: Discussionmentioning

confidence: 95%

“…14 In the study of Meador et al, no significant cognitive improvement was observed using small vinpocetine doses (maximum of 60 mg/day) in patients with and without epilepsy, and there were no significant adverse effects. 15 The doses they used were lower than those described in animal models. As most studies are based on animal models, further clinical trials are needed to demonstrate vinpocetine's efficacy in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Precision medicine: Vinpocetine as a potential treatment for GABRG2‐related epilepsy

Mandelenaki

Juvene

Lederer

et al. 2023

Epileptic Disorders

View full text Add to dashboard Cite

GABRG2 encodes the inhibitory GABAA (γ-aminobutyric acid type A) receptor γ2 subunit. GABAA receptors are the major mediators of fast inhibitory synaptic transmission in the central nervous system. The GABAA receptor belongs to a superfamily of ligand-gated ion channels, the majority containing two α subunits, two β subunits, and a γ or δ subunit. 1 GABRG2 pathogenic variants are associated with generalized epileptic syndromes, varying from simple febrile seizures and childhood absence epilepsy to more severe refractory phenotypes. [2][3][4] Vinpocetine, a synthetic vinca alkaloid derivative, has anti-inflammatory properties and the ability to inhibit

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Precision medicine: Vinpocetine as a potential treatment for GABRG2‐related epilepsy

Mandelenaki

Juvene

Lederer

et al. 2023

Epileptic Disorders

View full text Add to dashboard Cite

show abstract

“…With an observed functional potency of ~6 μM, vinpocetine is more potent at GABA A receptors than it is on most other reported targets (IC 50 values of 10–50 μM) 19 . Meador et al 13 . observed blood levels of vinpocetine of ~15 ng/ml in humans following peroral doses of 20 mg three times daily.…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy of vinpocetine on epileptic seizures has previously been investigated. Meador et al 13 . treated eight patients with focal epilepsy with 20 mg vinpocetine three times daily without observing significant seizure reduction or any significant side effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss‐of‐function variant

Gjerulfsen,

Mieszczanek,

Johannesen

et al. 2023

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Vinpocetine is a synthetic derivative of the alkaloid vincamine and has been used as a dietary supplement for decades. Following a positive report of the use of vinpocetine in a patient with a loss‐of‐function GABRB3 variant, we here describe another patient with a loss‐of‐function GABRA1 variant (p.(Arg112Gln)) who benefited from vinpocetine treatment. This patient was diagnosed with autism spectrum disorder, psychiatric complications, and therapy‐resistant focal epilepsy. Upon add‐on treatment with 40 mg vinpocetine daily for 16 months, the patient experienced an overall improved quality of life as well as seizure freedom. Our findings corroborate that vinpocetine can attenuate epilepsy‐associated behavioral issues in patients with loss‐of‐function GABAA receptor gene variants.

show abstract

New insights on the potential effect of vinpocetine in Parkinson’s disease: one of the neglected warden and baffling topics

Al-Kuraishy

Alexiou²,

Papadakis

et al. 2023

Metab Brain Dis

View full text Add to dashboard Cite

Vinpocetine (VPN) is an ethyl apovincaminate that has anti-inflammatory and antioxidant effects by inhibiting the expression of nuclear factor kappa B (NF-κB) and phosphodiesterase enzyme 1 (PDE-1). VPN is used in the management of stroke, dementia, and other neurodegenerative brain diseases. VPN may be effective in treating Parkinson’s disease (PD). Therefore, this review aimed to clarify the mechanistic role of VPN in the management of PD. VPN has protective and restorative effects against neuronal injury by reducing neuroinflammation, and improvement of synaptic plasticity and cerebral blood flow. VPN protects dopaminergic neurons by reducing oxidative stress, lipid peroxidation, glutamate neurotoxicity, and regulation of Ca+ 2 overloads. VPN can alleviate PD neuropathology through its anti-inflammatory, antioxidant, antiapoptotic and neurogenic effects. VPN through inhibition of PDE1 improves cyclic adenosine monophosphate (cAMP)/cyclic guanosine monophosphate (cGMP) signaling in the dopaminergic neurons of the substantia nigra (SN). VPN improves PD neuropathology through PDE1 inhibition with a subsequent increase of the cAMP/cGMP signaling pathway. Therefore, increasing cAMP leads to antioxidant effects, while augmentation of cGMP by VPN leads to anti-inflammatory effects which reduced neurotoxicity and development of motor severity in PD. In conclusion, this review indicated that VPN could be effective in the management of PD.

show abstract

Vinpocetine, cognition, and epilepsy

Cited by 13 publications

References 43 publications

Precision medicine: Vinpocetine as a potential treatment for GABRG2‐related epilepsy

Precision medicine: Vinpocetine as a potential treatment for GABRG2‐related epilepsy

Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss‐of‐function variant

New insights on the potential effect of vinpocetine in Parkinson’s disease: one of the neglected warden and baffling topics

Contact Info

Product

Resources

About